Molecular Breast Imaging (MBI) emerges as a pivotal force in the USA breast cancer screening, offering efficiency, affordability, and precision.

NEWARK, DELAWARE, UNITED STATES OF AMERICA, October 12, 2023 /EINPresswire.com/ -- By 2033, the global molecular breast imaging market is projected to have grown from its 2022 valuation of US$ 846.7 million to US$ 1.4 billion. With a value share of about 56.7%, the screening application led the global market for that application category in 2022. Over the course of the forecast period (2023 to 2033), it is anticipated to grow at a compound annual growth rate (CAGR) of almost 4.8%.

Molecular breast imaging (MBI) is a novel nuclear medicine approach that provides high-resolution functional pictures of the breast using tiny semiconductor-based -cameras in a mammographic configuration. MBI is a reasonably straightforward procedure that may be completed within 5 minutes after injection. MBI offers a high sensitivity for identifying tiny breast lesions, with an overall sensitivity of 90% in individuals with suspected breast cancer, according to studies.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-7701

Tumor detection is determined on tumor size rather than tumor type. MBI and breast-specific imaging studies have showed equal sensitivity to breast MRI. Efforts have been undertaken over the last decade to improve existing imaging techniques, such as digital tomosynthesis and 3D whole-breast ultrasonography, or to create novel imaging modalities, such as breast CT, vibro-acoustography, or positron emission mammography (PEM).

In general, the market for molecular breast imaging is likely to expand more in the coming next years. This market provides people with a cheap and rapid way to diagnose illness.

Key Takeaways:

By modality, dual head camera accounted for prominent share in the global market, with a valuation of US$ 519.9 Billion in 2022. Dual-head molecular breast imaging captures images in craniocaudal, medial, and lateral regions.

With a valuation of US$ 480.1 Million in 2022, the screening application accounted for a significant portion of the global market. MBI is a sensitive imaging technique for screening breast cancer in dense breast tissue, with a lower false-positive rate, improving early detection and potentially saving lives.

Hospitals held the prominent end user market share in the global market in 2022, growing rapidly with CAGR of 4.3% in predicted period. Hospitals use advanced imaging for accurate breast cancer detection, conducting clinical trials and research.

North America maintained the predominant regional position in the global molecular breast imaging market in 2022, with a revenue share of 5%. MBI offers low false-positive rates, good recall, quick interpretations, low cost, minimal contraindications, and strong negative predictive value, making the US a prominent market for molecular breast imaging in North America.

“Due to improved global breast cancer care and high safety, affordability, and accuracy offered by molecular breast imaging (MBI), the global market is projected to expand over the next decade,” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

Market Competition:

The molecular breast imaging market has several players making it a highly competitive market for players. Leading players constantly look out new tactics to maintain their foothold on the global market share. These include collaborations with healthcare institutes for new research programs and mergers or divestment to continue strengthening their portfolio among many others.

In April 2023, Canon Inc., Canon Medical Systems Corporation, and the National Cancer Center Japan conducted a clinical research using the first Japanese-produced PCCT system to develop new diagnostic methods, improving radiation exposure, pathological detectability, and precise identification of body materials.

In November 2022, GE HealthCare, a spin-off, showcases 40 AI-driven solutions to address healthcare challenges, including next-generation MRI, SIGNA Experience platform, Revolution Apex CT, and Theranostics' precision prostate cancer care. These solutions aim to scan more patients with less waste, improve patient outcomes, and enhance patient quality of life.

Key Companies:

Koninklijke Philips N.V. (Netherlands)
Hitachi Ltd. (Japan)
Siemens Healthcare GmbH (Germany)
CANON MEDICAL SYSTEMS CORPORATION (Japan)
General Electric (US)
Aspect Imaging Ltd (Israel)
Bruker (US),
Aurora Health Care (US)
FONAR Corp. (US)
ESAOTE SPA (Italy)
Neusoft Corporation (China)
TOSHIBA CORPORATION (Japan)
Sanrad Medical Systems Private Limited (India)
FUJIFILM Holdings Corporation (Japan)
ONEX Corporation (Canada)
Hologic, Inc. (US)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
Imaging Diagnostic Systems, Inc. (US)
Agfa-Gevaert Group (Belgium)
Koning Health (China)

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights:
https://www.futuremarketinsights.com/checkout/7701

Molecular Breast Imaging Market Segmentation:

By Modality:

Single Head Gamma Camera
Dual Head Camera

By Application:

Screening
Diagnosis

By End User:

Hospital
Diagnostic Imaging Centers
Breast Cancer Care

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Explore Future Market Insights, Inc. Extensive Coverage in Healthcare Market Domain:

Medical Hyperspectral Imaging Market Outlook: Expanding at a CAGR of 6.2%, the market is projected to increase from a valuation of US$ 181.8 Million in 2022 to US$ 294.7 Million by the end of 2030.

Electronic Medical Records (EMR) Market Sales: The market size is estimated to be valued at US$ 17.6 billion in 2023 and is projected to surpass a valuation of US$ 32.3 billion by 2033. The adoption is likely to rise at a CAGR of 6.2% during the forecast period.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Ankush Nikam
Future Market Insights, Inc.
+91 90966 84197
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.